Roth Capital Increases Regeneron Pharmaceuticals Price Target to $345.00 (REGN)
Posted by Wayne Rhoads on Oct 16th, 2013 // No Comments
Equities research analysts at Roth Capital upped their price target on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $319.00 to $345.00 in a research note issued to investors on Wednesday, AR Network reports. Roth Capital’s price target would suggest a potential upside of 12.14% from the stock’s previous close.
A number of other analysts have also recently weighed in on REGN. Analysts at Brean Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note to investors on Wednesday. Separately, analysts at Barclays raised their price target on shares of Regeneron Pharmaceuticals from $305.00 to $339.00 in a research note to investors on Thursday, October 10th. They now have an “overweight” rating on the stock. Finally, analysts at TheStreet reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note to investors on Tuesday, October 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating and sixteen have issued a buy rating to the stock. Regeneron Pharmaceuticals presently has an average rating of “Buy” and an average price target of $281.94.